Jan 12 2010
NicOx S.A. (NYSE Euronext Paris: COX) today announced that NicOx and
TOPIGEN Pharmaceuticals Inc. have mutually terminated their collaboration
for TPI 1020. This decision was made as a result of the acquisition of
TOPIGEN by Pharmaxis announced yesterday.
Following two phase 2a studies that were conducted by TOPIGEN with TPI 1020
in patients with asthma and COPD, NicOx and TOPIGEN had recently been in
active discussions to explore potential new opportunities for the
development of TPI 1020 in a variety of respiratory indications. As a
result of the strategic review of Pharmaxis and TOPIGEN's development
pipeline, they have decided not to move forward with the development of TPI
1020.
The licensing and co-development agreement between NicOx and TOPIGEN on TPI
1020, a novel anti-inflammatory drug-candidate for respiratory indications,
was signed in October 2005.
NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a pharmaceutical company
focused on the research, development and future commercialization of drug
candidates. NicOx is applying its proprietary nitric oxide-donating R&D
platform to develop an internal portfolio of New Chemical Entities (NCEs)
for the potential treatment of inflammatory, cardio-metabolic and
ophthalmological diseases.
NicOx's lead investigational compound is naproxcinod, an NCE and a first-
in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-
inflammatory drug candidate for the relief of the signs and symptoms of
osteoarthritis. NicOx submitted a New Drug Application (NDA) for
naproxcinod to the US Food and Drug Administration (FDA) in September 2009
and a Marketing Authorization Application (MAA) to the European Medicines
Agency (EMEA) in December 2009, following the successful completion of
three pivotal phase 3 studies. The NDA for naproxcinod was accepted for
filing by the FDA in November 2009 and the FDA has set a target date of
July 24 2010, for the completion of its review.
In addition to naproxcinod, NicOx's pipeline includes several nitric oxide-
donating NCEs, which are in development internally and with partners,
including Merck & Co., Inc., for the treatment of widespread eye diseases,
cardiometabolic diseases, hypertension and dermatological disease.
SOURCE: NICOX
New approach to stabilize RSV protein could lead to better vaccines